Nifty Pharma News and Updates

Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 4
Author: Geojit BNP Paribas

Keep track of all breaking news on Nifty Pharma from all sources in a single place.

Load latest

Glenmark Pharmaceuticals Ltd.

09 Sep 2025

1952.70

-0.28%

Glenmark Pharma subsidiary IGI gets $700 million upfront payment from AbbVie

Business Line

The Mumbai-based drugmaker had in July announced this deal on itsdrug candidate that was in early Phase-I clinical trials and had shown promising outcomes in patients with relapsed / refractory multiple myeloma

Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2011.6

Glenmark Pharma shares rise as arm receives an upfront payment of $700 mn

Business Standard | 09 Sep 2025

Glenmark Pharmaceuticals Ltd.

09 Sep 2025

1952.70

-0.28%

GLENMARK PHARMACEUTICALS

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Glenmark Pharmaceuticals Ltd, which has a presence in over 80 countries, focuses on the generics, specialty and over-the-counter (OTC) segments, with a strong presence in diabetes, cardiovascular and oral contraceptives....

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.

Mankind Pharma Ltd.

08 Sep 2025

2435.70

-1.07%

Mankind Pharma gets CDSCO nod for Phase 1 trials for novel autoimmune drug

Business Standard

Mankind Pharma has received CDSCO approval to initiate Phase 1 trials of MKP11093, a novel JAK-1 inhibitor for autoimmune disorders, as part of its expanding R&D pipeline

Mankind Pharma Ltd. is trading below all available SMAs

CDSCO clears Mankind's Phase 1 trial for autoimmune disorder molecule

Business Standard | 08 Sep 2025

Cipla Ltd.

08 Sep 2025

1503.30

1.03%

Growth outlook intact despite near-term headwinds

Hold: Cipla Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +0.9%/-5.2%, as we factor in lower revenue on account of ramp down of Revlimid portfolio and ongoing price erosion in the US market, higher depreciation and amortization expense, offset by higher other income.

Cipla Ltd. is trading below its 30 day SMA of 1557.3

Sun Pharmaceutical Industries Ltd.

05 Sep 2025

1594.30

0.31%

Pharma market grows 8.7% in August; cardiac and anti-diabetic segments lead

Business Standard

The Indian Pharma Market grew 8.7% in August 2025, with the cardiac, anti-diabetic, and anti-neoplastic segments driving growth. Sun Pharma maintained its leadership position

Sun Pharmaceutical Industries Ltd. is trading below all available SMAs

Cipla Ltd.

05 Sep 2025

1503.30

1.03%

Cipla launches Huena, India's first non-antibiotic drug to fight UTI

Business Standard

Drug firm Cipla on Friday said it has introduced a non-antibiotic treatment for patients suffering from recurrent urinary tract infections. The company has launched Methenamine Hippurate under the brand name HUENA. This marks a significant step forward for the company in its fight against anti-microbial resistance as it becomes the first to introduce such treatment in India, the Mumbai-based drugmaker said in a statement. Urinary tract infections (UTIs) are the second most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. Women are more susceptible to UTIs, which account for 15 per cent of overall antibiotic prescriptions. Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies show it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance. "We believe this...

Cipla Ltd. is trading below its 30 day SMA of 1557.3

Biocon Ltd.

05 Sep 2025

341.00

0.25%

Biocon shares gain 2% after USFDA inspection at Bengaluru facility; details

Business Standard

The inspection covered various aspects of operations including drug substance manufacturing units, analytical quality control laboratories, microbiology laboratories, and warehouses

Mutual Funds have increased holdings from 8.77% to 15.24% in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

04 Sep 2025

3603.20

0.46%

Torrent Pharma Announces Open Offer To Acquire Rs 6,843-Crore Stake In JB Chemicals

NDTV Profit

Once the deal is finalised, Torrent Pharmaceuticals will become India's second most valued pharma company.

Torrent Pharmaceuticals Ltd. is trading at high day volume of 627.6K.

Lupin Ltd.

03 Sep 2025

1911.30

-1.13%

Lupin Gets USFDA Nod For Generic Risperidone Extended-Release Injectable Suspension

NDTV Profit

The medicine had estimated annual sales of $190 million in the US, Lupin said, citing IQVIA moving annual toal July 2025 data.

Lupin Ltd. is trading below all available SMAs

Lupin gets USFDA nod for generic risperidone extended-release injectable suspension

Business Line | 03 Sep 2025 1 more

Zydus Lifesciences Ltd.

03 Sep 2025

981.90

-1.03%

ZYDUS LIFESCIENCES LIMITED

Buy: Zydus Lifesciences Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Zydus Lifesciences Ltd (Zydus) is one of India's leading, vertically integrated pharmaceutical companies. It operates across the value chain, from manufacturing finished dosages to active pharmaceutical ingredients, as well as animal healthcare and wellness products. Zydus' revenue increased 5.9% YoY to Rs. 6,574cr in Q1FY26 driven by 6.5% YoY...

Zydus Lifesciences Ltd. is trading above its 200 day SMA of 949.3

Is Nifty Pharma worth buying?

324 Votes:

Buy 79.32%

Sell 11.73%

Hold 8.95%

Nifty Pharma PB	4.6
Nifty Pharma PE	33.1
Nifty Pharma DIV	0.7
Nifty Pharma EPS	648.8

Nifty Pharma PB

Nifty Pharma PE

Nifty Pharma DIV

Nifty Pharma EPS

Nifty Pharma News and Updates

Keep track of all breaking news on Nifty Pharma from all sources in a single place.